Coloplast's ESG event
22 March 2022

Improving products and packaging

Camilla Hjort Pagh
SVP, Global QA,
RA & Sustainability

We have a strengthened and clear governance of Sustainability

Board of Directors

Consists of six shareholder-elected and three employee-elected members.

Executive Leadership Team

Consists of CEO, CFO, Operations, Innovation, Growth, and People & Culture

Remuneration and Nomination Committee

Consists of four members appointed among the Board of Directors.

Audit Committee

Consists of three members appointed among the Board of Directors.

Sustainability unit

Dedicated team for Sustainability including Employee Health & Safety (EHS) with the responsibility of embedding sustainability in the organization and identifying new improvement areas. Anchored in Global Operations.

Sustainability is a core element of our Strive25 strategy, with a strong focus on improving our environmental performance

Our mission

Making life easier for people with intimate healthcare needs

3 GOOD HEALTH AND WELL-BEING

Our 2025 priority

Improving products and packaging

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

Our 2025 priority

Reducing Emissions

13 CLIMATE ACTION

Our ongoing commitment

Responsible operations

5 GENDER EQUALITY

8 DECENT WORK AND ECONOMIC GROWTH

10 REDUCED INEQUALITIES

DKK 250 million in investments allocated to sustainability efforts during Strive25 period

Coloplast

Providing a safe and healthy work environment for employees is a core focus for Coloplast

SafePlan (2.0) was launched to continue the focus on safety behaviours globally along with a target to reduce LTI frequency to 2.0 ppm by 2025 (2.3 in Q1 21/22)



Global crisis, such as COVID-19, are managed by a global task force, and employee health and safety are a core consideration when designing the response

Our response to COVID-19:

- Key priority to keep our employees safe while keeping production running to serve our customers with the products they need
- Global contingency plans and guidelines
- Multiple safety measures implemented at distribution centres and production sites to ensure production and distribution continue in a safe and stable way

Coloplast

Our mission to deliver safe and reliable products is supported by a unified global quality management system

Standards: uniform global processes to manage quality and risks throughout product development, production and distribution as well as post-market surveillance

Our ***quality management system*** lives up to strict regulatory standards, established by:

European Commission · FDA U.S. FOOD & DRUG ADMINISTRATION · ISO · 厚生労働省

Certifications: ***110 full days*** of audits on quality and system conformity in 2020/21, done by independent auditors and Notified Bodies

ISO 9001 · ISO 13485 · MDSAP MEDICAL DEVICE SINGLE AUDIT PROGRAM · EU MDD

Medical Device Regulation (MDR) compliance enables license to operate & sell; 75% of Coloplast revenue is MDR compliant*

Objective of MDR: *Products are safe* and can be freely and fairly traded throughout the EU

Main changes from MDD to MDR: Increased focus on clinical evidence, Post Market Surveillance and data transparency in the industry

Coloplast's journey to full MDR certification is a 7-year project period



*As of March 2022

Coloplast

We have an increased focus on eco-design and recyclability, without compromising product safety and performance

As a manufacturer of medical products made of plastic, Coloplast has a responsibility to contribute to solving the plastic waste problems.

We embrace that responsibility and have set clear priorities:

- Product safety and clinical performance cannot be compromised
- Single use products are the easiest and safest option for our users
- Sustainability should be easy for our users
- We need to identify new materials and support the development of new technologies
- Partnerships across the industry are essential

Read more on our position here: plastic-position-cp.pdf (coloplast.com)

Coloplast

Coloplast is mindful when selecting the materials and substances used in our products



- Coloplast products are biocompatible and safe for the intended purpose.
- We comply with international and local regulations and standards – including REACH, the California proposition 65 list, EU MDR, FDA, the EN ISO 10993-1:2020 and more.
- We monitor and track changes in regulations to identify and mitigate risks early on.
- If a hazardous substance is identified, the Coloplast Substance substitution group reviews and initiates a plan to investigate potential alternatives or eliminate the substance.

Read more on our position here: Report (coloplast.com)

Integrating sustainability in Innovation by including eco-design criteria to achieve a sustainable pipeline

3 GOOD HEALTH AND WELL-BEING

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

13 CLIMATE ACTION

Chemicals

Material type



Size and weight

Recyclability

Climate impact

Production waste

Coloplast

Improving products and packaging by addressing material use

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

Our secondary and tertiary packaging is already made of renewable materials. Focus is on redesigning primary packaging for minimal material use and/or switch to renewable materials.

Ongoing packaging projects include converting PET plastic trays to recycled PET plastic trays in Ostomy baseplates and protective seals within our supporting products portfolio.

Our 2025 ambitions:

90% of packaging is recyclable

80% of packaging consists of renewable materials

75% of production waste is recycled

Coloplast